Professor of Diabetic Medicine
- Diabetes Trials Unit Director
- NIHR Senior Investigator
- Honorary Consultant Physician
The DTU is a fully registered UKCRC Clinical Trials Unit and a founder member of OCDEM. It is one of only a handful of Academic Research Organisations (AROs) worldwide that specialise in performing diabetes-related mega trials. The DTU designs, runs and analyses large-scale Phase III & IV interventional clinical outcome trials nationally and internationally, often in collaboration with other AROs and pharmaceutical companies. Currently the DTU is undertaking 4 large-scale cardiovascular outcome trials in 40 countries, multiple translational trials, holds grants in excess of £60M and has a regional coordinating centre in Beijing, China.
The DTU Translational Trials Group evaluates novel treatments and devices for the therapy of diabetes trials and undertakes research into potential new therapeutic agents in Phase IIa/b trials. The DTU also undertakes major modelling and statistical programmes to utilise fully the data available from its many studies with a particular emphasis on modelling diabetes and cardiovascular disease processes. The DTU Informatics Group designs and maintains the specialist departmental software, the automated data handling facilities and the in-house electronic clinical trials management systems.
Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Davis TME. et al, (2018), Diabetes Obes Metab, 20, 1427 - 1434
Aspects of Multicomponent Integrated Care Promote Sustained Improvement in Surrogate Clinical Outcomes: A Systematic Review and Meta-analysis.
Lim LL. et al, (2018), Diabetes Care, 41, 1312 - 1320
A1C Targets Should Be Personalized to Maximize Benefits While Limiting Risks.
Riddle MC. et al, (2018), Diabetes Care, 41, 1121 - 1124
What does the Acarbose Cardiovascular Evaluation (ACE) trial tell us?
Holman RR., (2018), J Diabetes
Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants.
Theodorakis MJ. et al, (2018), Am Heart J, 199, 170 - 175